



Race Oncology Company Profile

Overview

Race Oncology is a specialty pharma company pursuing late stage drug assets overlooked by big pharma. Our first asset is a chemotherapy drug called Bisantrone, which was the subject of more than 40 phase II studies, before it was lost in a series of big pharma mergers during the 1990s.

We intend to complete final clinical development and seek regulatory approval in the US for relapsed/refractory Acute Myeloid Leukemia (AML).

Speaker Profile

Peter Molloy, Managing Director and CEO



Peter Molloy is the Managing Director and CEO of Race Oncology. His background includes 18 years in the pharmaceutical industry, including Managing Director of Pharmacia Australia and Vice President Strategic Marketing for Pharmacia in Asia/Pacific and Latin America.

Subsequently, he served as CEO of three biotech companies – Biota Holdings Ltd, SLIL Biomedical Corp and Florigene Ltd – where he managed numerous R&D programs, raised substantial equity funding and executed several pharmaceutical partnerships. During his three and a half years as CEO of ASX-listed Biota, the company's market value grew from approximately \$30m to nearly \$300m. Overall, during his career, he has managed eight biotechnology or pharmaceutical operations, launched 23 pharmaceutical products, including Betadine® OTC products, Somac® (pantoprazole) and Doryx® (doxycycline controlled-release), and executed 40 international licensing or distribution deals. He holds a BSc from the University of Melbourne (biochemistry/microbiology) and an MBA from the University of Adelaide.

He is also a Fellow of the Australian Institute of Company Directors and has served on several Australian and US boards as a non-executive director.